Kixta 100mg Palbociclib Price USA | Ernest Oncology Indian Exporter

Kixta 100mg Capsule: Advanced CDK4/6 Inhibition for Targeted Breast Cancer Therapy

Are you looking for a trusted Kixta 100 mg capsule exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced oral targeted therapies. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving medications reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Kixta 100mg?

Kixta 100mg is a high-potency oral capsule containing the active pharmaceutical ingredient Palbociclib. It belongs to a breakthrough class of medications known as Cyclin-Dependent Kinase (CDK) 4 and 6 inhibitors.

Manufactured by Zydus Healthcare Limited, Kixta 100mg is a precision-engineered therapy designed to combat specific types of advanced cancers by interfering with the molecular machinery of cell division. For international B2B procurement, Kixta offers a world-class, cost-effective alternative to innovator brands, providing critical support for patients with advanced-stage malignancies.

Primary Therapeutic Indications

Kixta 100 mg Capsule is clinically indicated for the management of:

1. HR+/HER2- Metastatic Breast Cancer: Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

2. Combination Therapy: It is typically prescribed in combination with endocrine-based therapies:

• With an aromatase inhibitor (such as letrozole) as initial endocrine-based therapy in postmenopausal women.

• With fulvestrant in women whose disease has progressed following endocrine therapy.

Mechanism of Action: How Kixta 100mg Works

Kixta (Palbociclib) utilizes a targeted approach to stop the progression of the cell cycle:

• CDK4/6 Inhibition: It selectively blocks cyclin-dependent kinases 4 and 6 (CDK4/6). These proteins act as "checkpoints" or switches that push cells from the growth phase (G1) into the DNA synthesis phase (S).

• Cell Cycle Arrest: By inhibiting these kinases, Kixta prevents cancer cells from dividing and multiplying. This "arrests" the cancer cell cycle, effectively slowing tumor growth.

• Synergistic Effect: When combined with anti-estrogen therapies, it further reduces the phosphorylation of the retinoblastoma (Rb) protein, leading to a more profound inhibition of cancer cell proliferation compared to hormonal therapy alone.

Administration and Safety Guidelines

• Administration: The standard dose is one 100mg capsule taken orally once daily for 21 consecutive days, followed by 7 days off treatment (a 28-day cycle).

• With Food: Kixta should be taken with food to maintain consistent drug levels in the blood. Swallow the capsule whole; do not chew, crush, or open it.

• Key Precautions:

  • Neutropenia: This medication can significantly lower white blood cell counts. Regular Complete Blood Counts (CBC) are mandatory before and during treatment.

  • Infection Risk: Patients should immediately report signs of fever or chills to their oncologist.

  • Lung Inflammation: Patients should be monitored for new or worsening respiratory symptoms (e.g., dry cough or shortness of breath).

  • Avoid Grapefruit: Grapefruit and grapefruit juice can increase the levels of the medicine in your body and should be avoided.

Why Source Kixta 100 mg from Ernest Oncology?

• Strategic Indian Exporter: Direct access to Zydus’ manufacturing excellence, ensuring 100% authenticity and competitive bulk pricing for international B2B markets.

• Logistics Mastery: Expertise in navigating the regulatory and customs landscapes of the USA, UK, Australia, and South Africa.

• Bulk Supply Reliability: We specialize in large-scale exports for oncology hospitals, specialty clinics, and regional distributors, ensuring treatment continuity.

• Regulatory Support: Every shipment is accompanied by a Certificate of Analysis (COA) and verified documentation to facilitate seamless global customs clearance.